July 5, 2011
Tibotec Pharmaceuticals announced on June 28 that it has entered into a license agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily, single-tablet, fixed dose antiretroviral combination product containing Tibotec's protease inhibitor Prezista (darunavir) and Gilead's cobicistat, an investigational "boosting" agent. Prezista has, up until now, been boosted with Norvir (ritonavir).
In the U.S., once-daily dosing of Prezista is indicated for treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance-associated substitutions.
"We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product which has the potential to reduce the number of tablets patients take. Tibotec is committed to developing new and innovative HIV treatment options, especially those which provide simplified treatment regimens that may help patients to better manage their HIV treatment. Prezista is one of the leading protease inhibitors and co-formulating it with cobicistat in a new combination product demonstrates our commitment to HIV and innovations that will provide new options for patients," said Johan Van Hoof, M.D., Global Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen Pharmaceuticals.
Subject to regulatory approval, Tibotec will be responsible for the formulation, manufacturing, registration, distribution, and commercialization of the Prezista and cobicistat fixed dose combination worldwide. Gilead retains sole rights for the manufacture, development, and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
According to Tibotec's press release, the companies are also negotiating terms for the development and commercialization of a future single-tablet regimen (STR) combining Prezista with Gilead's Emtriva (emtricitabine), and its investigational agents GS 7340 and cobicistat. Gilead would be responsible for the development and commercialization of the new STR on a worldwide basis.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.